China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its product, Epione. Epione is an in-licensed puncture surgery navigation and positioning system designed for navigation and positioning in adult abdominal solid organ puncture surgery.
Origin and Commercialization of Epione
Epione was originally developed by Quantum Surgical, which entered into a joint venture with Lifetech in Dongguan, China in 2019. The partnership aimed to commercialize Epione within the Chinese market. With this marketing approval, Epione is now poised to be actively applied in the treatment of various abdominal solid organ tumors, including liver cancer, kidney cancer, and pancreatic cancer.
Broadening the Scope of Precision Surgery in China
The NMPA’s approval of Epione marks a significant step forward in the field of precision surgery in China. The system’s ability to aid in the navigation and positioning during complex abdominal surgeries is expected to enhance surgical outcomes and patient safety. This advancement aligns with the growing focus on precision medicine and the integration of advanced technologies in healthcare.-Fineline Info & Tech
